- Home
- BCAB vs ANTX Comparison
BCAB vs ANTX Comparison
Compare BCAB & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCAB
- ANTX
- Stock Information
- Founded
- BCAB 2007
- ANTX 2017
- Country
- BCAB United States
- ANTX United States
- Employees
- BCAB N/A
- ANTX N/A
- Industry
- BCAB Medicinal Chemicals and Botanical Products
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- BCAB Health Care
- ANTX Health Care
- Exchange
- BCAB Nasdaq
- ANTX Nasdaq
- Market Cap
- BCAB 31.5M
- ANTX 34.2M
- IPO Year
- BCAB 2020
- ANTX 2022
- Fundamental
- Price
- BCAB $0.79
- ANTX $1.29
- Analyst Decision
- BCAB Hold
- ANTX Buy
- Analyst Count
- BCAB 3
- ANTX 2
- Target Price
- BCAB $1.00
- ANTX $2.00
- AVG Volume (30 Days)
- BCAB 953.7K
- ANTX 81.8K
- Earning Date
- BCAB 11-06-2025
- ANTX 11-12-2025
- Dividend Yield
- BCAB N/A
- ANTX N/A
- EPS Growth
- BCAB N/A
- ANTX N/A
- EPS
- BCAB N/A
- ANTX N/A
- Revenue
- BCAB $11,000,000.00
- ANTX N/A
- Revenue This Year
- BCAB N/A
- ANTX N/A
- Revenue Next Year
- BCAB N/A
- ANTX N/A
- P/E Ratio
- BCAB N/A
- ANTX N/A
- Revenue Growth
- BCAB N/A
- ANTX N/A
- 52 Week Low
- BCAB $0.24
- ANTX $0.98
- 52 Week High
- BCAB $2.53
- ANTX $1.68
- Technical
- Relative Strength Index (RSI)
- BCAB 66.59
- ANTX 60.03
- Support Level
- BCAB $0.63
- ANTX $1.25
- Resistance Level
- BCAB $0.89
- ANTX $1.37
- Average True Range (ATR)
- BCAB 0.07
- ANTX 0.08
- MACD
- BCAB 0.00
- ANTX -0.00
- Stochastic Oscillator
- BCAB 70.47
- ANTX 39.57
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.